Dosing and uses of Privine (naphazoline)
Adult dosage forms and strengths
nasal spray
- 0.05% (20mL)
Nasal Decongestant
1-2 sprays per nostril q6hr PRn
Pediatric dosage forms and strengths
nasal spray
- 0.05% (20mL)
Nasal Decongestant
< 12 years
- Not recommended
>12 years
- 1-2 sprays per nostril q6hr PRN
Privine (naphazoline) adverse (side) effects
Frequency not defined
CNS (anxiety, dizziness, tremor, etc)
Burning
Stinging
Sneezing
Dryness
Local irritation
Rebound congestion
Warnings
Contraindications
Heart disease (incr BP, HR, palpitations)
Narrow angle glaucoma
Cautions
Caution in HTN, hyperthyroidism, ocular injury, DM, open-angle glaucoma
Overuse may cause rebound congestion
Pregnancy and lactation
Pregnancy category: C
Lactation: not known if excreted in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Privine (naphazoline)
Mechanism of action
Alpha 1 adrenergic agonist; stimulates alpha-adrenergic receptors in nasal conjunctiva and arterioles to produce vasoconstriction that results in nasal decongestion
Pharmacokinetics
Absorption: minimal systemic
Onset: 10 min
Duration: 2-6 hr
